Saving ears and kidneys from cisplatin

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4183-4188

  Wensing, Kristina U ^a   Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cisplatin; Protection; Review; Toxicity; Transporters; Tumor; Uptake

Indexed keywords

CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; UNCLASSIFIED DRUG;

COCHLEA; DOWN REGULATION; DRUG TRANSPORT; DRUG TUMOR LEVEL; EPIGENETIC REPRESSION; KIDNEY CELL; NEPHROTOXICITY; NERVE CELL; OTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

CISPLATIN; PROTECTION; REVIEW; TOXICITY; TRANSPORTERS; TUMOR; UPTAKE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; CISPLATIN; COCHLEA; CYTOPROTECTION; HUMANS; KIDNEY; ORGANIC CATION TRANSPORT PROTEINS;

EID: 84891370666     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
2. Ishida S, Lee J, Thiele DJ and Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-302, 2002.
3. Blair BG, Larson CA, Safaei R and Howell SB: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15: 4312-4321, 2009.
4. Samimi G, Katano K, Holzer AK, Safaei R and Howell SB: Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66: 25-32, 2004.
5. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J and Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-84, 2005.
6. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, Am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H and Schlatter E: Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176: 1169-80, 2010.
7. Yonezawa A, Masuda S, Yokoo S, Katsura T and Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319: 879-86, 2006.
8. Nakamura T, Yonezawa A, Hashimoto S, Katsura T and Inui KI: Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80: 1762-1767, 2010.
9. Fillastre JP and Raguenez-Viotte G: Cisplatin nephrotoxicity: Toxicol Lett 46: 163-75,1989.
10. Daugaard G: Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37: 1-12, 1990.
11. Pabla N and Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
12. Litterst CL, Gram TE, Dedrick RL, LeRoy AF and Guarino AM: Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36: 2340-2344, 1976.
13. Dobyan DC, Levi J, Jacobs C, Kosek J and Weiner MW: Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213: 551-556, 1980.
14. Skinner R: Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 40: 2352-2354, 2004.
15. Rybak LP: Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15: 364-369, 2007.
16. Albers JW, Chaudhry V, Cavaletti G and Donehower RC: Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev CD005228, 2011.
17. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L and Cavaletti G: Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20: 883-887, 1999.
18. Amptoulach S and Tsavaris N: Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract Article ID 843019, 5 pages, 2011.
19. Extra JM, Espie M, Calvo F, Ferme C, Mignot L and Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990.
20. Kuo YM, Zhou B, Cosco D and Gitschier J: The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA 98: 6836-6841, 2001.
21. Nose Y, Rees EM and Thiele DJ: Structure of the Ctr1 copper trans'PORE'ter reveals novel architecture. Trends Biochem Sci 31: 604-607, 2006.
22. Aller SG and Unger VM: Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. Proc Natl Acad Sci USA 103: 3627-3632, 2006.
23. Lee J, Prohaska JR and Thiele DJ: Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci USA 98: 6842-6847, 2001.
24. Lee J, Pena MM, Nose Y and Thiele DJ: Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 277: 4380-4387, 2002.
25. Yonezawa A and Inui K: Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81: 563-568, 2011.
26. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R and Howell SB: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66: 817-823, 2004.
27. Safaei R and Howell SB: Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53: 13-23, 2005.
28. Holzer AK, Manorek GH and Howell SB: Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70: 1390-1394, 2006.
29. Larson CA, Blair BG, Safaei R and Howell SB: The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75: 324-330, 2009.
30. Lin X, Okuda T, Holzer A and Howell SB: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62: 1154-1159, 2002.
31. Pabla N, Murphy RF, Liu K and Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296: F505-F511, 2009.
32. More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR and Giacomini KM: Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 30: 9500-9509, 2010.
33. Ding D, He J, Allman BL, Yu D, Jiang H, Seigel GM, Salvi RJ: Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res 282: 196-203, 2011.
34. van Ruijven MW, de Groot JC and Smoorenburg GF: Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res 197: 44-54, 2004.
35. Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF and McKeage MJ: Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 64: 847-856, 2009.
36. Jamieson SM, Liu J, Connor B and McKeage MJ: Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56: 391-399, 2005.
37. Tomiwa K, Nolan C and Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 69: 295-308, 1986.
38. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N and Kuo MT: Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. Mol Cancer Ther 11: 2483-2494, 2012.
39. Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, Song TJ, Kim MK, Kim TJ, Lee JW, Bae DS and Kim BG: Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol 122: 361-365, 2011.
40. Xu X, Duan L, Zhou B, Ma R, Zhou H and Liu ZQ: Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol 39: 786-792, 2012.
41. Ivy KD and Kaplan JH: A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 83: 1237-1246, 2013.
42. Ciarimboli G, Holle SK, Vollenbroker B, Hagos Y, Reuter S, Burckhardt G, Bierer S, Herrmann E, Pavenstädt H, Rossi R, Kleta R and Schlatter E: New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm 8: 270-279, 2011.
43. Ciarimboli G and Schlatter E: Regulation of organic cation transport. Pflügers Arch 449: 423-441, 2005.
44. Koepsell H, Schmitt BM and Gorboulev V: Organic cation transporters. Rev Physiol Biochem Pharmacol 150: 36-90, 2003.
45. Wright SH, Dantzler WH: Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84: 987-1049, 2004.
46. Koepsell H, Lips K and Volk C: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24: 1227-1251, 2007.
47. Ciarimboli G: Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7: 159-174, 2011.
48. Ciarimboli G: Organic cation transporters. Xenobiotica 38: 936-971, 2008.
49. Koepsell H and Endou H: The SLC22 drug transporter family. Pflügers Arch 447: 666-676, 2004.
50. Reece PA, Stafford I, Russell J and Gill PG|: Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis- dichlorodiammineplatinum (II). Cancer Chemother Pharmacol 15: 295-299, 1985.
51. Pan BF, Sweet DH, Pritchard JB, Chen R and Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci 47: 181-186, 1999.
52. Endo T, Kimura O and Sakata M: Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology 146: 187-195, 2000.
53. Filipski KK, Loos WJ, Verweij J and Sparreboom A: Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14: 3875-3880, 2008.
54. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T and Inui K: Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70: 1823-1831, 2005.
55. Ludwig T, Riethmuller C, Gekle M, Schwerdt G and Oberleithner H: Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66: 196-202, 2004.
56. Kolb RJ, Ghazi AM and Barfuss DW: Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl- L-cysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother Pharmacol 51: 132-138, 2003.
57. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S and Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51: 913-921, 1997.
58. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE and Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16: 871-881, 1997.
59. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H and Brandsch M: Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70: 1851-1860, 2005.
60. Taubert D, Grimberg G, Stenzel W and Schomig E: Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS ONE2: e385, 2007.
61. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H and Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res 18: 1528-1534, 2001.
62. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y and Inui K: Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461: 339-342, 1999.
63. Asaka J, Terada T, Okuda M, Katsura T and Inui K: Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm Res 23: 697-704, 2006.
64. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86: 396-402, 2009.
65. Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N, Sai Y and Miyamoto K: Protecting Cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33: 1867-1871, 2010.
66. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF and Sparreboom A: Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 110: 11199-11204, 2013.
67. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ and Giacomini KM: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66: 8847-8857, 2006.
68. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ and Wiemer EA: Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159: 898-908, 2010.
69. Yang J, Kalogerou M, Gallacher J, Sampson JR and Shen MH: Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur J Cancer 49: 1479-1490, 2013.
70. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H and Schwab M: DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 3: 82, 2011.
71. Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE, Simko J, Chen X, Costello JF and Giacomini KM: Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J 13: 110-120, 2013.